The experience of monoclonal antibody to interleukin 17 (secukinumab) use in case of spondyloarthrites in real clinical practice conditions


V.P. Tyurin, S. Ju. Davidjan, N.A. Kirjukhina

Federal State Budgetary Institution National N.I. Pirogov Centre of medicine and surgery of the Ministry of Healthcare of Russia, Moscow.
The article touches upon the modern aspects of pathogenesis of spondyloarthrites, Russian experience of secukinumab - genetically engineered biological medicine, first in Russia monoclonal 17A interleukin antibody use for that group of the diseases. The data of performing analysis show, that biological therapy with secukinumab inclusion helps significantly decrease ankylosing spondylitis and psoriatic arthritis activity, improve functional condition of resistant patients without adverse events risk increase. Significant and fast decrease of laboratory inflammation indexes, articular syndrome decrease in case of spondyloarthrites gives us the basis to consider secukinumab to be a perspective medicine for “switching” the patients with insufficient efficacy of α anti-tumor necrosis factor agents in anamnesis to biological agent with another mechanism of action.
Keywords: secukinumab, 17A interleukin antibody, α anti-tumor necrosis factor agents, spondyloarthrites, genetically engineered biologic drugs
Read entire article

Literature

  • Эрдес Ш.Ф., Бадокин В.В., Бочкова А.Г. и др. О терминологии спондилоартритов. Научно-практическая ревматология.2015; 53(6): 657-60 [Erdes Sh.F., Badokin V.V., Bochkova A.G. et al. On the terminology of spondyloarthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015; 53(6): 657-60 (In Russ.)]. doi: 10.14412/1995-4484-2015-657-660.
  • Braun J., Sieper J. Ankylosing spondylitis.Lancet. 2007 Apr 21; 369(9570):1379–90.
  • Rudwaleit M., van der Heijde D., Khan M.A. et al. How to diagnose axial spondyloarthritis early. Ann Rheum Dis. 2004 May; 63(5): 535–43. DOI:http:// dx.doi.org/10.1136/ ard.2003.011247.
  • Годзенко А.А. Анкилозирующий спондилит. В кн. Ревматология. Клинические лекции. Под ред. В.В. Бадокина. Москва:Литтерра; 2014. 124 с. [Godzenko A.A.Ankylosing spondylitis. In: Revmatologiya. Klinicheskie lektsii [Rheumatology. Clinical lectures]. Badokin V.V., editor. Moscow:Litterra; 2014. 124 p.]
  • McGonagle D. A proposed classification of the immunological diseases. PLOS Med. 2006; 3: e297. doi:10.1371/journal.pmed.0030297.
  • Baeten D. et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis N Engl J Med 2015;373:2534-48.DOI: 10.1056/NEJMoa1505066.
  • Mease P. et al. Secukinumab: A New Treatment Option for Psoriatic Arthritis. Rheumatol Ther. 2016 Jun; 3(1): 5-29. doi: 10.1007/s40744-016-0031-5. Epub 2016 Apr 23.
  • Schoels M.M., Braun J., Dougados M. et al. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. Ann Rheum Dis. 2014; 73(1): 238-42. doi: 10.1136/annrheumdis-2013-203860.
  • Van der Heijde D., Ramiro S., Landewe R. et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017. doi: 10.1136/annrheumdis-2016-210770.
  • Гайдукова И.З., Ребров А.П., Оттева Э.Н. и др. Применение нестероидных противовоспалительных препаратов для лечения аксиальных спондилоартритов, включая анкилозирующий спондилит, мониторинг эффективности и безопасности (проект рекомендаций группы экспертов по диагностике и лечению спондилоартритов). Научно- практическая ревматология. 2016; 54(Прил 1): 67-74.
  • Лапшина С.А., Дубинина Т.В., Бадокин В.В. и др. Ингибиторы фактора некроза опухоли α в лечении аксиальных спондилоартритов, включая анкилозирующий спондилит. Научно-практическая ревматология. 2016; 54(Прил 1): 75-9.
  • Braun J., Brandt J., Listing J. et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet (Lond). 2002; 359(9313): 1187-93. doi: 10.1016/S0140- 6736(02)08215-6.
  • Davis J.C., van der Heijde D., Braun J. et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003; 48(11): 3230-6. doi: 10.1002/art.11325.
  • Inman R.D., Davis J.C., van der Heijde D. et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008; 58(11): 3402-12. doi: 10.1002/art.23969.
  • Landewe R., Braun J., Deodhar A. et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study. Ann Rheum Dis. 2014; 73(1): 39-47. doi: 10.1136/annrheumdis-2013-204231.
  • Van der Heijde D., Dijkmans B., Geusens P. et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005; 52(2): 582-91. doi: 10.1002/art.20852.
  • Van der Heijde D., Kivitz A., Schiff M.H. et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.Arthritis Rheum. 2006; 54(7): 2136-46. doi: 10.1002/art.21913.
  • Erdes Sh.F., Denisov L.N., Maslyansky A.L. et al. Anti-interleukin-17 monoclonal antibody for the treatmentof ankylosing spondylitis: Results of analysis of a Russian patient group from the randomized, double-blind,placebo-controlled MEASURE 1 and MEASURE 2 trials. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017; 55(1): 17-25 (In Russ.). doi: http://dx.doi.org/10.14412/1995-4484-2017-17-25.
  • Резюме Совета экспертов «Вопросы „выживаемости” генно-инженерных биологических препаратов и возможности переключения на секукинумаб при анкилозирующем сподилите в реальной клинической практике». Москва. 10 февраля 2017 г. Научно-практическая ревматология. 2017; 55(2): 230–231.
  • Braun J. et al. Ann Rheum Dis. 2017 Jun;76(6):1070-1077. doi: 10.1136/annrheumdis-2016-209730. Epub 2016 Dec 13. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study.
  • Научно-практическая ревматология. 2017;55(2):230–231.


    • About the Autors

    Vladimir P. Tyurin, MD, professor, head of internal medicine Department of medical refresher Institute of Federal State Budgetary Institution «National N.I. Pirogov Centre of medicine and surgery» of the Ministry of Healthcare of the Russian Federation.
    Satenik Ju. Davidjan, PhD, rheumatologist, «National N.I. Pirogov Centre of medicine and surgery» of the Ministry of Healthcare of the Russian Federation.
    Natalya A. Kirjukhina, rheumatologist, «National N.I. Pirogov Centre of medicine and surgery» of the Ministry of Healthcare of the Russian Federation.


    Similar Articles

    Back to Content

    Бионика Медиа